Hypocalcemia after parathyroidectomy in patients taking proton pump inhibitors

Lorenz, Fryderyk; Goldenberg, David

doi:10.1016/j.amjoto.2022.103761

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, their prolonged use has been associated with hypomagnesemia, rebound acid secretion, and vitamin deficiencies. [1][2][3][4][5][6][7][8][9] Administration of PPIs involves various formulations designed to resist premature activation by stomach acid. They are typically taken before meals to maximize effectiveness, with delayed onset compared to other acidreducing drugs.…”

Section: Introductionmentioning

confidence: 99%

A study on appropriate use and stewardship of proton pump inhibitors

Mondal,

Maity,

Phawa

et al. 2024

IJPP

View full text Add to dashboard Cite

Objective: To analyze the prescribing pattern of use of PPI with respect to “FDA-Approved Indications and Doses for PPI Therapy.” Materials and Methods: After obtaining approval from the Institutional Ethics Committee, a cross-sectional study was carried out among 400 inpatients in a tertiary care hospital in Bangalore. The data were collected from the patient case profile and prescriptions and noted in a self-designed data collection form. The statistical analysis of the collected data was performed using SPSS software and Excel. Results: The study, conducted on 400 patients, revealed a male majority (60%) and a female representation of 40%. Proton Pump Inhibitors (PPIs), mainly Pantoprazole (74.70%), were frequently prescribed, notably in General Medicine (220 patients). PPI use was generally appropriate: indication (99%), dose (97%), frequency (92.8%), and duration (91.8%). However, irrational prescriptions were noted: indication (1%), dose (3%), frequency (7.3%), and duration (8.3%). 139 drug interactions were identified, categorized into Major (39.6%), Moderate (46%), and Minor (14.4%). For example, Ondansetron and tramadol exhibited a major interaction. Among PPI combinations, 93.75% could affect CYP2C19 metabolism, and 6.3% had additive/synergistic toxicity potential.

show abstract